PRQR.US ProQR Therapeutics BV

Healthcare Biotechnology USA Stocks
1.21 USD
Close of Nov 17, 2026
1.12 2.49
Market cap
USD 171M
P/E
-
P/B
2.26x
ROE
-68.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PRQR.US undervalued?

Graham number

The Graham number of ProQR Therapeutics BV cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ProQR Therapeutics BV fundamental analysis

No fundamental analysis for ProQR Therapeutics BV yet.

ProQR Therapeutics BV stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ProQR Therapeutics BV

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein…

Full company profile